Inside Salk - July 2012 - page 9

Inder Verma
pioneers the use of
stripped-down versions of viruses to
insert genes into cells throughout the
body, paving the way for gene therapy
trials in cancer patients.
Ronald Evans
identifies the first of
a large family of molecules, named
“nuclear receptors,” which are primary
targets in the treatment of breast cancer,
prostate cancer and leukemia.
and his lab identify the
central player that stands guard over
the stability of the genome, a protein
called p53, which is often disarmed in
cancer cells.
Salk scientists continue Dulbecco’s
legacy, explaining how a popular class
of chemotherapy drugs works, discovering
a new target for lung cancer drugs
and showing that stem cells in develop-
ing organsmay help us understand the
genetic underpinnings of cancer.
Inside Salk 07|12
Lead Story
Top left: FrancisCrick, Jonas Salk andRenatoDulbecco at
aparty at the La Jolla Playhouse hosted by theWomen’s
Association for the Salk Institute, October 1994.
Top right: Dulbecco in the lab, 1978.
Second row: Dulbecco accepting theNobel Prize in Physiology
orMedicine in 1975 for hiswork on reverse transcriptase.
Third row left: Dulbeccowith 1987Nobel laureate
Susumu Tonegawa.
Third row right: Dulbecoo andQueenElizabeth II in 1974.
Bottom row, from left: WilliamR. Brody, Roger Guillemin,
andRenatoDulbecco, 2011.
1,2,3,4,5,6,7,8 10,11,12,13,14,15,16,17,18,19,...32
Powered by FlippingBook